Literature DB >> 18580734

Aspirin for primary prevention of coronary heart disease: using the Framingham Risk Score to improve utilization in a primary care clinic.

Steven C Romero1, Kristina M Dela Rosa, Peter E Linz.   

Abstract

OBJECTIVES: Coronary heart disease (CHD) is the number one cause of death in adults in the industrialized world, and several large studies show that aspirin is helpful for the primary prevention of this disease. Unfortunately, few physicians are aware of its benefit, resulting in the underutilization of aspirin for the primary prevention of CHD. The purpose of this study was to demonstrate the underuse of aspirin for the primary prevention of CHD, and to improve appropriate utilization by implementing an easy-to-use clinic tool that quickly estimates a patient's risk. PATIENTS AND METHODS: This is a retrospective cohort analysis conducted in the Internal Medicine Clinic in the Naval Medical Center in San Diego, California. Random samples of 494 patients before and 593 after intervention who were followed in the Internal Medicine Clinic were screened. Inclusion criteria were a 10-year risk of myocardial infarction or coronary death of more than 10%, or diabetes with one other cardiac risk factor. A poster was placed in each clinic examination room showing the Framingham Risk Score, the indications for aspirin use, and common contraindications to assist physicians in determining if a patient warranted aspirin for primary prevention of CHD. A physician documented regular use of aspirin, 81 to 325 mg per day.
RESULTS: Age and sex demographics were similar between the two measurement groups. Diabetics comprised a significantly greater percentage of patients in the postintervention group. There was a trend toward increase in utilization of aspirin from 63.5% to 72.8% (P = 0.054) after our intervention. In subgroup analysis, significant improvement in appropriate aspirin use was found amongst males (P = 0.01) and nondiabetics (P = 0.02).
CONCLUSION: Aspirin has proven beneficial in the primary prevention of CHD, but is clearly underutilized in this role. By implementing the Framingham Risk Score to streamline the decision process, appropriate utilization can be improved, and in turn, cardiac events can be reduced and patients can benefit.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18580734     DOI: 10.1097/SMJ.0b013e318178e58e

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

Review 1.  Solid tumor second primary neoplasms: who is at risk, what can we do?

Authors:  Kevin C Oeffinger; Shrujal S Baxi; Danielle Novetsky Friedman; Chaya S Moskowitz
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

2.  Use of Aspirin and Statin as primary prevention for cardiovascular diseases.

Authors:  Bahaa Aba Alkhail; Rahila Iftikhar; Adnan Al Shaikh
Journal:  Pak J Med Sci       Date:  2016 Nov-Dec       Impact factor: 1.088

3.  Dynamic platelet function: A novel biomarker in inflammatory arthritis?

Authors:  Eithne Nic An Riogh; Eimear Dunne; Sharon Cowley; Kelly Leamy; Geraldine McCarthy; Dermot Kenny; John Stack
Journal:  PLoS One       Date:  2022-01-25       Impact factor: 3.240

4.  Aspirin use in rheumatoid arthritis patients with increased risk of cardiovascular disease.

Authors:  Jonida K Cote; Androniki Bili
Journal:  ISRN Rheumatol       Date:  2013-11-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.